Piaza - Non-interventional Study on the Efficacy and Safety of Azacitidin (Vidaza) in Patients With Myelodysplastic Syndromes (MDS, INT-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder)

Trial Profile

Piaza - Non-interventional Study on the Efficacy and Safety of Azacitidin (Vidaza) in Patients With Myelodysplastic Syndromes (MDS, INT-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder)

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2015

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms Piaza
  • Most Recent Events

    • 12 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 26 Aug 2015 Planned End Date changed from 1 Jul 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
    • 09 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top